A Pilot Study to Evaluate for the Abscopal Effect of Durvalumab (Anti-PD-L1) in Combination With Definitive Radiation Therapy in Solitary Bone Plasmacytoma With Limited Clonal Bone Marrow Plasmacytosis
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Durvalumab (Primary)
- Indications Plasmacytoma
- Focus Therapeutic Use
- 02 Aug 2018 Status changed from suspended to withdrawn prior to enrolment as per FDA recommendation
- 18 Sep 2017 Status changed from recruiting to suspended.
- 27 Jul 2017 Status changed from not yet recruiting to recruiting.